Menin inhibitor maintenance after stem cell transplant for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests giving a menin inhibitor drug after a stem cell transplant to help prevent acute myeloid leukemia (AML) from coming back. You may be eligible if your AML has certain gene changes and you are planning your first transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have AML in remission with a KMT2A rearrangement, NPM1 mutation, or NUP98 rearrangement.
- You are planning your first stem cell transplant from a matched or haploidentical donor.
- Your heart, lungs, kidneys, and liver are working well enough for transplant.
- You have not had active AML right before transplant.
- You are willing to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new drug called a menin inhibitor works in patients with acute myeloid leukemia (a blood cancer) who have relapsed after receiving a stem cell transplant. Researchers want to understand which patients benefit most by studying specific markers in their blood.
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
This trial tests an all-pill (oral) combination treatment—menin inhibitor SNDX-5613 plus decitabine/cedazuridine (ASTX727) and venetoclax—for acute myeloid leukemia (AML). It’s designed for people who are newly diagnosed and can’t get the strongest chemotherapy, or for certain other AML groups who may still benefit.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Hear when a new Relapsed Adult AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.